97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

Andrew Robinson, David Vicente, Ali Tafreshi, Héctor Soto Parrà, Julien Mazières, I. Cicin, Balazs Medgyasszay, Jerónimo Rafael Rodríguez‐Cid, Isamu Okamoto, S. Lee, Rodryg Ramlau, Vladimir Vladimirov, Yin Cheng, Balázs Halmos, Liu Cc, Paul Schwarzenberger, Bilal Piperdi, Luis Paz‐Ares